sluit venster

Log in

Gebruikersnaam Wachtwoord Gebruikersnaam en/of wachtwoord vergeten? Gebruikersnaam en wachtwoord aanvragen

Zoek in de HOVON website

Let op!
Mogelijk ziet u niet alle beschikbare info op deze pagina, omdat u niet bent ingelogd, of omdat u niet de juiste privileges heeft.

Clinical picture: NHL (Non Hodgkin Lymphoma)

Trial: HOVON 25 NHL / OG 95-004

1. Overview
Study details
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
6. Instruction videos
7. Download documentation / forms

return to top


No news

1. Overview


Effect of Recombinant G-CSF on the Results of Chemotherapy (CHOP) in Elderly Patients with Intermediate-/High-Grade Non-Hodgkin's Lymphoma: A Prospective Phase III Study.



Study details

Type of study

Prospective randomized Phase III study

Target number of patients


Date of activation


Approved by

Dutch Cancer Foundation: CKVO 94-01
National Health Council of the Netherlands: OG 95-004

2. Patient eligibility criteria

Inclusion criteria

Patients with previously untreated Non-Hodgkin�s Lymphoma, Ann Arbor stages II-IV, of intermediate- or high-grade malignancy.
Patients with age 65 years or more.
Informed consent.

Exclusion criteria

Patients aged less than 65
Patients who have been treated for Non-Hodgkin�s Lymphoma by chemotherapy or radiotherapy.
Other malignant diseases, except localized squamous skin carcinoma.
Severe heart failure.
Inadequate liver or renal function.
Failure to give informed consent.
HIV positivity.

3. Registration (& randomization) of patients


Central registration at the HOVON Data Center:
Erasmus MC Cancer Institute, Clinical Trial Center (Hs-423)
P.O. Box 2040
NL-3000 CA Rotterdam
Phone number.: +31.10.7041560 (working days 9.00-17.00)
Fax number.....: +31.10.7041028
TOP address...:

Registration criteria

The following information will be requested:

Name institute
Name of caller and/or physician in charge
Hospital record number
Patient name, date of birth and sex
Pathology diagnosis
Stage II, III or IV, A/B
Serum LDH

4. Participating parties

Principal investigator

P Sonneveld (

Coordinating investigator(s)

JK Doorduijn (


W.L.J. van Putten (
B. van der Holt (

Trial manager

MMC Steijaert (

Central data management

MMC Steijaert (

Other functions

Cost-Effectiveness Analysis:
FFH Rutten
C Uyl
Central Pathologist:
AH Mulder (

Please contact monitors at

5. Participating sites

6. Instruction videos

7. Download documentation / forms

return to top